On June 1, 2021 Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, reported the launch of elio (empowering local insight for oncology) plasma complete, a NGS kit solution for comprehensive blood-based genomic analysis (Press release, Personal Genome Diagnostics, JUN 1, 2021, View Source [SID1234583343]). The elio plasma complete kit is intended to support research in areas like biomarker discovery, therapy selection, and monitoring, and is ideal for investigating genetic mutations and genomic signatures in multiple cancer types.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to launch elio plasma complete, the third NGS kit on our elio platform, developed specifically to meet the growing needs of scientists researching genetic biomarkers of tumors directly from blood samples," said Megan Bailey, Chief Executive Officer of PGDx. "This sample-to-answer solution brings a high quality, easy to use, comprehensive genomic profiling tool and the flexibility of a liquid biopsy format to the research community in a way never seen before. By launching this product, we hope to enable researchers and our biopharma partners to identify new biomarkers and develop new insights that inform new precision oncology medicine approaches and empower the fight against cancer."
From a simple blood draw, elio plasma complete analyzes circulating cell-free tumor DNA present in plasma for genetic alterations in cancer, eliminating the need for an invasive biopsy or tumor tissue. PGDx elio plasma complete evaluates even low-abundance sample DNA and processes samples using a high coverage next-generation sequencing panel of 521 genes. Through the elio testing platform, elio plasma complete also includes automated bioinformatics that supports the identification of somatic mutations within cell-free DNA with high sensitivity and specificity.
The launch of elio plasma complete follows PGDx’s previously released elio tissue complete and elio plasma resolve products. PGDx elio plasma complete is currently available globally for Research Use Only (RUO).